European Companies Search Engine
UK funding (£293,149): Inhibitory anti-CD3 antibodies to switch off activated T cells in man Ukri1 Jul 2008 UK Research and Innovation, United Kingdom
Overview
Text
Inhibitory anti-CD3 antibodies to switch off activated T cells in man
| Abstract | Many of the common diseases of the developed world are caused by the immune system responding to harmless molecules such as foods or plant materials, or responding to the bodies own tissues. One particular type of immune cell, called a T cell, controls these tissue-damaging responses. This proposal aims to find a way to switch off the disease causing T cells by targeting a molecule on their surface in such a way as to render the cell inactive. |
| Category | Research Grant |
| Reference | G0800746/1 |
| Status | Closed |
| Funded period start | 01/07/2008 |
| Funded period end | 30/06/2011 |
| Funded value | £293,149.00 |
| Source | https://gtr.ukri.org/projects?ref=G0800746%2F1 |
Participating Organisations
| Queen Mary University of London |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Queen Mary University of London, London.
The visualizations for "Queen Mary University of London - UK funding (£293,149): Inhibitory anti-CD3 antibodies to switch off activated T cells in man"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
